|
Below
we would like to introduce you to our two newest Focus Stocks,
Angiotech Pharmaceuticals (Nasdaq: ANPI) and Headwaters Inc.
(NYSE: HW), which we feel will out perform the market in the
near-term. To
learn more about these Companies and other equities visit our website
here
Angiotech
Pharmaceuticals (Nasdaq: ANPI)
Website:
www.angiotech.com
Redefining
Success
Overview
Angiotech Pharmaceuticals
(ANPI) operates as a specialty pharmaceutical and medical
device company. It discovers, develops, and markets technologies
and medical products for local diseases and complications
associated with medical device implants, surgical interventions,
and acute injury.
ANPI offers various technologies
that improve the performance of medical devices and the outcomes
of surgical procedures. These technologies include various drug,
drug delivery, and surface modification materials and other
medical biomaterials designed to be applied across a range of
medical devices and technologies, surgical procedures, and medical
disciplines.
Angiotech also manufactures and
markets single use, specialty medical devices, with products
focused primarily on general surgery; oncology and tumor biopsy;
interventional radiology and vascular surgery; ophthalmology; and
aesthetic surgery.
Its product candidates that are
undergoing human clinical trials include TAXUS Liberte paclitaxel-eluting
coronary stent system, which is related to the use of paclitaxel
to prevent restenosis and other local inflammatory diseases;
ZILVER PTX paclitaxel-eluting peripheral vascular stent that is
designed for placement in diseased arteries in the limbs to
restore blood flow; Vascular Wrap, a paclitaxel-eluting mesh
surgical implant designed to treat complications associated with
vascular graft implants in patients undergoing hemodialysis or
have peripheral artery disease; and Anti-Infective Catheter
related to central venous catheters.
Angiotech has license agreement
with Boston Scientific Corporation, Cook Group Incorporated, and a
distribution and license agreement with Orthovita Inc. The Company
also has a manufacturing and supply agreement with Baxter
Healthcare Corporation; a collaboration agreement with Genzyme
Corporation and CombinatoRx Inc, and a strategic alliance
agreement with Athersys Inc.
Intellectual property includes over
150 issued U.S. patents and 185 pending U.S. patent applications.
The combined global company has over 1,500 employees
worldwide.
For the
latest Quote and News on ANPI visit.
To learn more
about Angiotech Pharmaceuticals visit.
Headwaters
Inc. ( NYSE:
HW)
Website:
www.hdwtrs.com
Adding
Value to Energy
Overview
Headwaters Incorporated (HW)
through its subsidiaries, provides products, technologies, and
services to the energy and construction materials industries in
the United States. It operates in three segments: Construction
Materials, Coal Combustion Products, and Alternative Energy.
The Construction
Materials segment designs, manufactures, and markets shutters,
gable vents, mounting blocks, tools, and architectural
manufactured stones. This segment also provides concrete blocks
and other masonry units, as well as various mortars and stucco
products.
The Coal Combustion
Products segment markets coal combustion products, such as fly ash
and bottom ash to the building products and ready mix concrete
industries.
The Alternative
Energy segment develops catalyst technologies to convert coal and
heavy oil into liquid fuels, as well as nanocatalyst processes and
applications.
For the
latest Quote and News on HW visit.
To learn more
about
Headwaters Inc.
visit.
SmallCapReview
feature stock reports are intended to be ideas, NOT
recommendations. Please do your own research before investing. It
is crucial that you at least look at current SEC filings and read
the latest press releases. For continuing coverage of ANPI
and HW please sign up for our free newsletter. Information contained
in this report was extracted from current documents filed with the
SEC, the company web site and other publicly available sources
deemed reliable. For more information see our disclaimer section,
a link of which can be found on our web site. SCR has
not been compensated by Angiotech Pharmaceuticals or Headwaters
Inc. for its efforts in presenting the respective profiles on its website and distributing it to its database
of subscribers, nor do we hold any shares at this time. SCR may decide to purchase or
sell shares on a voluntary basis in the open market before, during
or after the profiling period of this report.
The Reader should verify all claims
and do their own due diligence before investing in any securities
mentioned. Investing in small-cap securities is speculative and
carries a high degree of risk.
We
encourage our readers to invest carefully and read the investor
information available at the web sites of the Securities and
Exchange Commission (SEC) at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD)
at: http://www.nasd.com.
Readers can review all public filings by companies at the SEC's
EDGAR page. The NASD has published information on how to invest
carefully at its web site.
|
